Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia

Primary hypothesis: Hyperglycemia during inpatient therapy of AML is associated with increased mortality (fewer hospital free days to Day 60, see below). * H1a: Hyperglycemia will result in an increased risk of developing clinical signs of infection (fever). * H1b: Hyperglycemia will be associated with an increased risk of developing severe sepsis after the onset of clinical signs of infection (fever). o H1b1: Hyperglycemia will be associated with the development of acute lung injury after the onset of signs of infection (fever). * H1c: Hyperglycemia will be associated with an increased risk of ICU admission. o H1c1: Hyperglycemia will be associated with an increased risk of ICU admission for severe sepsis. * H1d: Hyperglycemia will be associated with an increased risk of death in those subjects with severe sepsis (fewer hospital free days to Day 60, see below). Secondary Aim: To investigate whether TSP-1 is important in modulating the course of sepsis-induced acute lung injury. Secondary hypothesis: In patients with sepsis, increased levels of functional TSP-1 will be associated with a lower incidence of and a less severe course of lung injury. * H2a: In human sepsis, increased TSP-1 levels will be associated with a lower incidence of lung-injury. * H2b: In human sepsis, increased TSP-1 levels will be associated with a less severe course of lung-injury. * H2c: In human sepsis, patients with the Asn682Ser polymorphism in the TSP-1 gene will be associated with a higher incidence of lung-injury. * H2d In human sepsis, patients with the Asn682Ser polymorphism in the TSP-1 gene will be associated with a more severe course of lung-injury.